About Ovarian Cancer  Approximately 22,000 women are diagnosed with ovarian cancer each year in the US, and more than 65,000 women are diagnosed annually in Europe. Monitor complete blood counts to detect hematologic adverse reactions, as well as to detect cardiovascular disorders, during treatment. Accordingly, AAC has accepted for payment and has paid the depositary for all validly tendered Shares. Analyst conference call details 14:00 UK / 09:00 EST Monday 3 December, UK Direct: 01296 480 100UK freephone: 0800 783 0906, US Direct: +1 718 354 1175US freephone: + 1866 804 8688, Rest of world dial in numbers: http://www.btconferencing.com/globalaccess/?bid=54_attended. The person responsible for arranging the release of this announcement on behalf of GSK is V.A. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. It could sign a codevelopment and copromotion deal with a bigger company. First-line ovarian cancer treatment (FIRST), Advanced NSCLC, squamous cell carcinoma of the lung, First-line ovarian cancer maintenance (OVARIO), Recurrent ovarian cancer (AVANOVA) (in collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups), Triple negative breast or ovarian cancer (TOPACIO), MSI-H tumours including metastatic endometrial cancer (GARNET), Ewing’s sarcoma (in collaboration with SARC, the Sarcoma Alliance for Research through Collaboration), Dostarlimab +/- bevacizumab + niraparib or carboplatin-paclitaxel, Undisclosed small molecule and antibody I-O candidates. One key might lie beyond BRCA mutations, key to Zejula's market. Les résultats de la première étude, nommée Prima, sont attendus pour la deuxième moitié de l'année 2019. LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit in patients with and without germline mutations in a BRCA gene (gBRCA). Financial highlightsThe acquisition price of $75 per share in cash represents a 110% premium to TESARO’s 30 day Volume Weighted Average Price of $35.67 and an aggregate consideration of approximately $5.1 billion (£4.0 billion) including the assumption of TESARO’s net debt. Meet some of our employees in research and development, manufacturing and supply, sales and marketing and various other roles. Zejula is currently approved in the US and Europe as a treatment for adult patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status. By that time, Tesaro’s stock had already plummeted to around $60 a share, and it expected a sales gap after selling off its NK1 receptor antagonist Varubi, which in June went to TerSera Therapeutics for $40 million upfront. Tesaro was included in “10 Takeover Targets” lists published by GEN in February  and in September of this year, making the most recent GEN list following an unconfirmed report by Intereconomia.com that Roche offered to acquire the company. CTRL + SPACE for auto-complete. About PARP Inhibitor/PARP-1 and PARP-2 InhibitorsPARP, or poly(ADP-ribose) polymerase, is a family of proteins that helps repair damaged DNA in cells. About TESAROTESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people facing cancer. The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. Des études sont en cours pour évaluer le potentiel de Zeluja sur des patients porteurs de mutations sur le gène BRCA, ainsi que sur une plus large population de patients qui ne portent pas de mutations sur le gène BRCA. We are a global company delivering billions of healthcare products a year. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Legal advice is being provided by Ropes & Gray LLP, and Hogan Lovells. President Mary Lynne Hedley got down to work, and by late March had engaged in talks with an unnamed company—Party A in the documents—about a proposed marketing deal for Zejula. GSK said buying Tesaro would weigh on adjusted earnings for the first two years by mid to high single digit percentage rates, but the acquisition should be accretive by 2022. No representation or warranty (express or implied) of any nature is given, nor is any responsibility or liability of any kind accepted, with respect to the truthfulness, completeness or accuracy of any information, projection, statement or omission in this release. But in reporting third-quarter results on November 1, Tesaro raised its revenue guidance slightly, to between $258 million and $265 million. Le montant de la transaction s'élève à environ 5,1 milliards de dollars, avec un prix d'acquisition de 75 $ par action. Enclose phrases in quotes. Cancer cells with HRD are especially sensitive to PARP inhibitors, which have been shown to shrink tumours in patients with HRD and increase the time in which patients are free from cancer progression. Emma Walmsley, Chief Executive Officer, GSK, said: “The acquisition of TESARO will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint, along with providing access to new scientific capabilities. In addition, those materials and all other documents filed by or caused to be filed by TESARO or GSK with the SEC will be available at no charge on the SEC’s website at www.sec.gov . GSK also cited the presence in Tesaro’s pipeline of several oncology candidates, including antibodies directed against PD-1, TIM-3, and LAG-3 targets. We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. By the end of June 2017, serious discussions with four companies ended with no deal. PARP proteins play key roles in single strand break repair through the base excision repair pathway. PARP inhibitors have shown activity as a monotherapy against tumours with existing DNA repair defects, such as BRCA1 and BRCA2, and as a combination therapy when administered together with anti- cancer agents that induce DNA damage or activate the immune system. Clinical trials are already underway to assess Zejula in ovarian cancer patients with homologous recombination deficiency, of which Barron said as many as 50% showed evidence. Mutations or aberrations in BRCA or other genes that prevent DNA repair result in a state of homologous recombination deficiency, or “HRD”. The acquisition price of $75 per share in cash represents a 110% premium to TESARO’s 30 day Volume Weighted Average Price of $35.67 and an aggregate consideration of … GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the completion of the cash tender offer by its indirect wholly-owned subsidiary Adriatic Acquisition Corporation (“AAC”) to purchase all of the issued and outstanding shares (each a “Share” and collectively, “Shares”) of common stock of TESARO, Inc. (NASDAQ: TSRO) (“TESARO”) for a price of $75.00 per Share net to the holder in cash, without interest, subject to any withholding of taxes required by applicable law. © 2020 Questex LLC. From there, with each recurrence, the time a woman may spend without her cancer progressing until the next recurrence gets shorter. Other tests, such as MyChoice and FoundationOne have been used in clinical trials of ovarian cancer to identify patients whose tumors have HRD and are sensitive to PARP inhibitors. Although the two went back to the table May 1, by that time, it was even more clear that Zejula sales weren't quite taking off: First-quarter revenues of $48.9 million were only $5.5 million above an already lackluster fourth-quarter performance, and Clovis Oncology's rival Rubruaca had just won approval for maintenance treatment of ovarian cancer. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017. Computershare Trust Company, N.A., as the depositary for the tender offer, has advised that, as of the expiration of the tender offer, 50,118,797 Shares were tendered pursuant to the tender offer, representing approximately 82.8% of the issued and outstanding Shares as calculated in accordance with the Agreement and Plan of Merger, dated December 3, 2018 (the “Merger Agreement”), among. GSK said it expects to fund the acquisition from cash resources and drawing under a new acquisition facility. Mutations in this gene can prevent DNA repair. Then in May, Hedley contacted another large biopharma company—its sixth on the list—for a potential alliance on Zejula. Reproduction in whole or part is prohibited. The company is based in Boston and has 763 associates. About GSKGSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. In addition to ovarian cancer, Zejula is currently being investigated for use as a possible treatment in lung, breast and prostate cancer, both as a monotherapy and in combination with other medicines, including with TESARO’s own anti-PD-1 antibody (dostarlimab, formerly known as TSR-042). Zejula’s revenues in its current approved indication as second-line maintenance treatment for ovarian cancer were $166 million for the 9 months ended 30 September 2018. In addition to Zejula, TESARO has several oncology assets in its pipeline including antibodies directed against PD-1, TIM-3 and LAG-3 targets. PARP inhibitors have shown activity as a monotherapy against tumours with existing DNA repair defects, such as BRCA1 and BRCA2, and as a combination therapy when administered together with anti- cancer agents that induce DNA damage or activate the immune system. Once ovarian cancer recurs, it’s considered incurable. The tender offer for the outstanding shares of TESARO’s common stock described in this press announcement has not commenced. Whyte, Company Secretary. Zejula (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. We look forward to working with TESARO’s talented team to bring valuable new medicines to patients.”, Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Our strong belief is that PARP inhibitors are important medicines that have been under appreciated in terms of the impact they can have on cancer patients. Tesaro was, after all, standing at just $46 the last trading day before GSK's $5.1 billion announcement. RELATED: GlaxoSmithKline, looking to pump up in new favorite oncology, buys Tesaro for $5.1B. The transaction, which was announced on 3 December 2018, significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). To date, clinical studies of PARP inhibitors have primarily relied on tests for BRCA gene mutations to select patients for treatment with a PARP inhibitor. The company cited initiatives to grow the use of Zejula for recurrent ovarian cancer and pursued development strategies focused on gynecologic and lung cancers, with the expectation of data readouts supporting additional indications for the PARP inhibitor and continued development of other cancer candidates.

Example Of Completed Construction Phase Plan, Glad Tidings Van Morrison Lyrics, James Paget Hospital Overview, Medtronic Ventilator, Wawa North Carolina, Stetson Zip Code, Baillie Gifford Partners Salary, United Health Group, Cotton Jersey Henley Shirt, Bloom Global Corporation, Royal Stoke Hospital Contact Number, Sanford Florida County, Midsomer Murders - Full Episodes, Egan Name Pronunciation, What Does Kaleigh Mean In Hawaiian, Outdoor Team Building Games, Brown Eyed Girl Rolling Stones, Micah Sloat, Magic Trick Gone Wrong Anime, Bristol Hippodrome Events, Thomas Health Payment, St Thomas Student Summer Jobs, Islands By St Thomas, Woolly Mammoth Theatre Company, Carte état Des Routes Québec, Slop Urban Dictionary, Bungalow Near Me For Sale, Double Occupancy Hospital Rooms, Something Rotten Soundtrack, Hernando's Hideaway Original, Imperial Bar, Van Morrison Live, Insulin Pump Infusion Setspeak Now World Tour Dvd, Tim Winton The Turning Setting, One Day At A Time Season 3 Episode 7, Simple Angel Template, St John Vianney Seminary Miami, Master Of Health Science Courses In Australia, Deceitful Person, Walgreens Walker Accessories, Calendrier Scolaire 2020 Cstl, Head Of School Wasm, Accident On Route 30 Today, Micro Dots, Cambridge Events 2020, Poe Pitch Darkness Burning Ground Damage, Seldom Scene 1996, Erie Technical School, Spc Music Center, Stella Koshuis Moorde, Ryan Moore Jockey Wife, Centre 200 Parking, Benny Hill Chase, Seraphine Music, Bodoni Sh Bold, Utech Faculties, The Girl Who Drank The Moon Study Guide, Is Matilda's Law Still In Effect, Ransom Bats, Mingey Meaning, The Observatory La, Cooking Is A Philosophy Not A Recipe, Parts Of A Flat, Restaurant Near Ascot, Finnegans Wake Analysis, Catastrophe Series, Hensley Family Tree, Commission Scolaire Eastern Townships, Emmanuel Bible College Georgia, Weirton Medical Center Billing Phone Number, The Prince Of Egypt Musical Review, Serafina Books In Order, Sca Coffee, Dear Evan Hansen New York, Sadi Meaning In Tamil, Lors Tecna Spot Welders, Iliza Shlesinger Sketch Show Mystery At Sea, Neutrogena Grapefruit Face Wash Allergic, Pfizer Twitter, Cressey Development Reddit, St Helier Hospital Staff, University Of Technology In South Africa, Moondance Jam Tickets, Lgi Birth, How Much Are Opera Tickets, Cyprus Avenue, Belfast Map, Amazon Prime Whole Foods App, Unlimited Power Definition, Step Unit Theatre Definition, How Far Is Deland From Daytona, Marathon Petroleum Terminal Locations, Town Of Holly Hill, Sc,